Immunocore (IMCR) HR chief sells 1,000 shares, exercises RSUs

Rhea-AI Filing Summary

Immunocore Holdings plc reported insider transactions by Chief HR Officer Tina Amber St Leger. On February 18, 2026, she completed an open-market sale of 1,000 Ordinary Shares at a weighted average price of $32.35 per share, under a sell-to-cover arrangement to satisfy income tax liabilities from restricted stock unit vesting.

On February 17, 2026, 2,119 Restricted Share Units were exercised and converted into 2,119 Ordinary Shares at no cost, with each RSU representing one Ordinary Share. After these transactions, she directly held 1,119 Ordinary Shares and 6,357 RSUs.

Insider Trade Summary

Net Seller: 1,000 shares ($32,350)

Net Sell 3 txns

Insider St Leger Tina Amber

Role CHIEF HR OFFICER

Sold 1,000 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,000	$32.35	$32K
Exercise	Restricted Share Units	2,119	$0.00	--
Exercise	Ordinary Shares	2,119	$0.00	--

Holdings After Transaction: Ordinary Shares — 1,119 shares (Direct); Restricted Share Units — 6,357 shares (Direct)

Footnotes (1)

1. Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units ("RSUs"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each RSU represents a contingent right to receive one Ordinary Share. On February 17, 2025, the Reporting Person was granted 8,476 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

St Leger Tina Amber

(Last) (First) (Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON, OXFORDSHIRE X0 OX14 4RY

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF HR OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	02/17/2026		M		2,119	A	$0	2,119	D
Ordinary Shares(1)	02/18/2026		S		1,000(2)	D	$32.35(3)	1,119	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(4)	02/17/2026		M			2,119	(5)	(5)	Ordinary Shares(1)	2,119	$0	6,357	D

Explanation of Responses:

1. Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.

2. The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock units ("RSUs").

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $32.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. Each RSU represents a contingent right to receive one Ordinary Share.

5. On February 17, 2025, the Reporting Person was granted 8,476 RSUs, vesting in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Lily Hepworth, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Immunocore (IMCR) report for Tina Amber St Leger?

Tina Amber St Leger reported both a sale and an RSU conversion. She sold 1,000 Ordinary Shares in an open-market transaction and converted 2,119 Restricted Share Units into 2,119 Ordinary Shares in February 2026 as part of her equity compensation activity.

How many Immunocore (IMCR) shares did the chief HR officer sell and at what price?

The chief HR officer sold 1,000 Ordinary Shares at a weighted average of $32.35. Footnotes state the shares were sold in multiple trades between $32.17 and $32.70 per share, with the weighted average price reported for the overall transaction.

Why did Tina Amber St Leger sell Immunocore (IMCR) shares in this Form 4 filing?

The sale was made under a sell-to-cover arrangement for tax obligations. The filing explains that 1,000 shares were sold to satisfy income tax liabilities arising from the vesting of restricted stock units, rather than as a discretionary portfolio sale.

What RSU activity did Immunocore (IMCR) disclose for Tina Amber St Leger?

2,119 Restricted Share Units were exercised and converted into Ordinary Shares. Each RSU represents a contingent right to receive one Ordinary Share, and this conversion occurred on February 17, 2026, at a reported price of $0.00 per share for the derivative exercise.

How many Immunocore (IMCR) shares and RSUs does the officer hold after these transactions?

After the reported transactions, she held 1,119 Ordinary Shares and 6,357 RSUs. These holdings reflect the net effect of the 1,000-share sale and the conversion of 2,119 Restricted Share Units into Ordinary Shares disclosed in the Form 4.

What is the vesting schedule of the Immunocore (IMCR) RSUs granted to Tina Amber St Leger?

She was granted 8,476 RSUs on February 17, 2025, vesting over four years. The units vest in four equal annual installments beginning February 17, 2026, subject to her continuous service with Immunocore through each vesting date.